We're currently fundraising! Become an early investor in Bioverge to own an expanding portfolio of leading TechBio startups through a single investment 🔬! Learn more and invest today 💸!

Juno Diagnostics Investment

Juno Diagnostics, a San Diego based genetic diagnostics company in the Bioverge portfolio, just raised a $25 million Series A round led by Perceptive Xontogeny Venture Fund in May 2021.

C6jfl3hhtiohykcygh7t
C6jfl3hhtiohykcygh7t

Juno Diagnostics, a San Diego based genetic diagnostics company in the Bioverge portfolio, just raised a $25 million Series A round led by Perceptive Xontogeny Venture Fund in May 2021. 

While prenatal testing has been around for decades, methods such as an amniocentesis or chorionic villus sampling are invasive and carry a small, but very real risk of inducing a misscarriage. There is currently no good solution that offers an accurate, safe and noninvasive test for women to learn critical information early on in their pregnancy.

JunoDx is doing groundbreaking work creating a simple at-home prenatal genetics test based on cell-free DNA. Prior to founding JunoDx, the team worked together at Sequenom to pioneer the development and commercialization of the first cell-free DNA-based NIPT in the US. cDNA has been endorsed by many experts in the scientific community as a sensitive and reliable noninvasive test for fetal abnormalities.

Over the past decade, genetic sequencing and personalized medicine has taken off and become the standard for healthcare. Innovations in gene sequencing have made it more cost effective than ever to leverage genetic information to diagnose and cure diseases, as well as identify crucial information. JunoDx not only takes advantage of this, but also the trend towards simple and effective at-home care to create a product with the potential to impact millions of individuals looking to start or grow their family.

The recent round raised will help the team fund further research, clinical validation studies, product development, and excitingly, the commercial launch of their genetic testing product. JunoDx’s highly experienced team consisting of leading scientists, medical doctors, and engineers with over 100+ published peer reviewed articles and 90+ patents is well equipped to make the company a leader in prenatal genetic screening. 

Bioverge aims to invest in groundbreaking technology with the potential to impact millions, and JunoDx is just that. This funding is an exciting next step in helping JunoDx democratize reproductive healthcare by creating a simple, safe, and cost efficient solution in prenatal testing.